We are building a first-in-class drug development pipeline aimed at reinvigorating the immune system to combat cancer and inflammatory diseases.


Vigeo is currently developing therapies that activate the production of TSP-1, a naturally occurring potent immune system regulatory protein. TSP-1 has been shown to attack cancer cells and reduce inflammation at the cellular level.

Learn More

OUR <strong>APPROACH</strong>

Our clinical

We are currently enrolling patients the Phase 3 registration ready AGILE Study (NCT03970447) sponsored by Global Coalition for Adaptive Research (GCAR).

Working at

Find out more about a career at Vigeo


Latest News

March 26, 2024

Vigeo Therapeutics to Present at the 2024 Glioblastoma Drug Development Summit in Boston Massachusetts

Read More »

July 13, 2023

Vigeo Therapeutics Provides Clinical Update on VT1021 Treatment of GBM Expansion Patient

Read More »

June 02, 2023

Vigeo Therapeutics will present New Clinical and Immune Profiling Data from Ph I/II Expansion study in GBM Patients in ASCO Poster Oral Session

Read More »